ReviewCell transplantation
Xenopax from a real-world and economic perspective: The future of second-line treatment and prophylaxis for SR-aGVHD.
Review in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains a major therapeutic challenge after allogeneic hematopoietic stem cell transplantation. Although ruxolitinib and basiliximab are widely used, their limitations highlight the need for safer, more effective, and scalable biologic strategies. Xenopax, a humanized anti-CD25 monoclonal antibody, has demonstrated encouraging results across real-world and clinical studies. The multicenter RELAX study reported a 28-day overall response rate of 64.5% and a 2-year overall survival of 68.0%, with reduced corticosteroid exposure and infection rates compared with historical basiliximab cohorts. Importantly, RELAX incorporated an economic assessment, showing a lower incremental cost per responder and reinforcing xenopax as a cost-efficient option for SR-aGVHD. Beyond salvage therapy, xenopax is gaining momentum in prophylactic settings, including as a potential replacement for methotrexate in haploidentical transplantation. Looking ahead, integration with autonomous decision-support systems-most notably daGOAT, the first AI platform validated to prescribe risk-adapted GVHD prophylaxis-may further strengthen CD25-targeted approaches. Together, these developments position xenopax as a versatile biologic with the potential to reshape both treatment and prevention paradigms in GVHD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.